The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Joel P. Berger

Department of Molecular Endocrinology

Merck Research Laboratories


New Jersey 07065



Name/email consistency: high



  • Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA. 1996 - 2005
  • RY80N-C31, Merck Research Laboratories, 126 East Lincoln Avenue, Rahway, USA. 2003


  1. PPARs: therapeutic targets for metabolic disease. Berger, J.P., Akiyama, T.E., Meinke, P.T. Trends Pharmacol. Sci. (2005) [Pubmed]
  2. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. Berger, J.P., Petro, A.E., Macnaul, K.L., Kelly, L.J., Zhang, B.B., Richards, K., Elbrecht, A., Johnson, B.A., Zhou, G., Doebber, T.W., Biswas, C., Parikh, M., Sharma, N., Tanen, M.R., Thompson, G.M., Ventre, J., Adams, A.D., Mosley, R., Surwit, R.S., Moller, D.E. Mol. Endocrinol. (2003) [Pubmed]
  3. The mechanisms of action of PPARs. Berger, J., Moller, D.E. Annu. Rev. Med. (2002) [Pubmed]
  4. Physiological and therapeutic roles of peroxisome proliferator-activated receptors. Berger, J., Wagner, J.A. Diabetes Technol. Ther. (2002) [Pubmed]
  5. Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity. Berger, J., Tanen, M., Elbrecht, A., Hermanowski-Vosatka, A., Moller, D.E., Wright, S.D., Thieringer, R. J. Biol. Chem. (2001) [Pubmed]
  6. A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus. Berger, J., Patel, H.V., Woods, J., Hayes, N.S., Parent, S.A., Clemas, J., Leibowitz, M.D., Elbrecht, A., Rachubinski, R.A., Capone, J.P., Moller, D.E. Mol. Cell. Endocrinol. (2000) [Pubmed]
  7. Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. Berger, J., Leibowitz, M.D., Doebber, T.W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C.A., Hayes, N.S., Li, Y., Tanen, M., Ventre, J., Wu, M.S., Berger, G.D., Mosley, R., Marquis, R., Santini, C., Sahoo, S.P., Tolman, R.L., Smith, R.G., Moller, D.E. J. Biol. Chem. (1999) [Pubmed]
  8. A high-capacity assay for activators of glucose incorporation into glycogen in L6 muscle cells. Berger, J., Hayes, N.S. Anal. Biochem. (1998) [Pubmed]
  9. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Berger, J., Bailey, P., Biswas, C., Cullinan, C.A., Doebber, T.W., Hayes, N.S., Saperstein, R., Smith, R.G., Leibowitz, M.D. Endocrinology (1996) [Pubmed]
WikiGenes - Universities